TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06151158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+)
Description: Stanley Brown Safety Planning completed in the emergency department with 3 follow-up contacts after discharge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)
Description: Five session crisis focused version of IPT for adolescents.
Study: NCT06025500

Intervention type: DIAGNOSTIC_TEST
Intervention: 31P-Magnetic Resonance Spectroscopy (31P-MRS)
Description: 31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
Study: NCT06224192

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab Prefilled Syringe
Description: Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab Prefilled Syringe
Description: Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab AI
Description: AI for SC injection self-administration of rocatinlimab.
Study: NCT06334354

Intervention type: OTHER
Intervention: Assessments
Description: Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment

Intervention type: OTHER
Intervention: Assessments
Description: Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment

Intervention type: OTHER
Intervention: Assessment (Survivors Only)
Description: \*Tumor/Treatment Variables (Survivors Only)

Intervention type: OTHER
Intervention: APOE and DNA Isolation
Description: Biospecimens procurement and processing

Intervention type: OTHER
Intervention: APOE and DNA Isolation
Description: Biospecimens procurement and processing
Study: NCT06573697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-frequency continuous wave EA
Description: In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discontinuous wave EA
Description: In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dilatational wave EA
Description: In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
Study: NCT06579196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabedersen
Description: Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabedersen
Description: Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.
Study: NCT04872686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
Description: Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% PVP-I Oral and nasal spray to healthy volunteer
Description: Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software
Study: NCT05711745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calf myofascial technique
Description: A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
Study: NCT04756219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Video
Description: No additional information necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contact Video
Description: No additional information necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Text
Description: No additional information necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contact Text
Description: No additional information necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Video
Description: No additional information necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Video
Description: No additional information necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Text
Description: No additional information necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Text
Description: No additional information necessary.
Study: NCT05363345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bile duct stone removal
Description: Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bile duct stone removal
Description: Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
Study: NCT06531733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Promoting (pink noise)
Description: Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Promoting (pink noise)
Description: Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Promoting (pink noise)
Description: Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
Study: NCT05960708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35324
Description: Subcutaneous injection of YH35324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection of Omalizumab
Study: NCT06531733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wake Promoting (blue enriched light plus a nap)
Description: Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wake Promoting (blue enriched light plus a nap)
Description: Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wake Promoting (blue enriched light plus a nap)
Description: Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
Study: NCT05960708

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of None of active ingredient
Study: NCT05408910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG Oral Tablet [XIFAXAN]
Description: Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive placebo three times daily for 14 days.
Study: NCT06343142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuts
Description: Isocaloric meal with nuts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuts
Description: Isocaloric meal with nuts

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nut-free meal
Description: Isocaloric meal without nuts

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nut-free meal
Description: Isocaloric meal without nuts
Study: NCT06257966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-4 Fc fusion protein injection(1.2mg）
Description: 1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-4 Fc fusion protein injection（2.4mg）
Description: The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
Study: NCT05073536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-sized MCE
Description: Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.

Intervention type: DEVICE
Group type: OTHER
Intervention: normal-sized MCE
Description: Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
Study: NCT05398042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A daily dose of 3x20g of ketone ester supplementation during a six week intervention period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglyceride (MCT) oil
Description: A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
Study: NCT06529367

Intervention type: OTHER
Intervention: Snellen chart
Description: Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately.
Study: NCT06073665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Description: Levothyroxine dose will depend on dose at baseline and randomization group
Study: NCT06257966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: 1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin hydrochloride tablets, oral administration, 54 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride tablets, oral administration, 54 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
Study: NCT06565819

Intervention type: DIAGNOSTIC_TEST
Intervention: The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)
Description: DUS was used as reference criteria to screen out patients newly diagnosed with PAD during follow-up. In this study, NIR-II imaging results of patients at follow-up and initial examination were collected to obtain a threshold for early diagnosis.
Study: NCT06073665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Sodium
Description: Levothyroxine dose will depend on dose at baseline and randomization group
Study: NCT05462756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro (U100)
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (U100)
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (U100)
Description: Administered SC
Study: NCT06044298

Intervention type: OTHER
Intervention: procedural sedation
Description: Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed.
Study: NCT06535269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar Hemorroidecotmy
Description: Hemorrhoidectomy with monopolar diathermy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caiman Hemorroidectomy
Description: Hemorrhoidectomy with Caiman® bipolar energy
Study: NCT06410573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Self-Examination and Practice
Description: In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
Study: NCT05401292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hibiclens
Description: antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hibiclens
Description: antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isopropyl Alcohol 70% Topical Application Solution
Description: First aid antiseptic
Study: NCT06127069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chitosan brush
Description: debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
Study: NCT05572424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptated Physical Activity (APA) + pedometer watch
Description: Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps.
Study: NCT06340087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% Sucrose
Description: 10% sucrose corresponding to a regular soft drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose+ Hesperetin
Description: Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7% Sucrose
Description: 7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
Study: NCT06127069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic scaler
Description: debridement of periodontal pockets only with ultrasonic scaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic scaler
Description: debridement of periodontal pockets only with ultrasonic scaler
Study: NCT05654103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoAVF
Description: The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgAVF
Description: The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
Study: NCT06367374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.
Study: NCT05385016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Skills
Description: This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.